Replies to post #252792 on Biotech Values

[DewDiligence]

ELEV—(-38%)—pares pipeline—reduces workforce 70%:

https://finance.yahoo.com/news/elevation-oncology-discontinue-development-eo-120000342.html

ELEV is down 98% from its 2021 IPO (#msg-164599586).